167 related articles for article (PubMed ID: 25131865)
1. [Abiraterone acetate(ZYTIGA®)-development and literature review].
Nishimura Y; Mukai H; Suzukawa K; Oyama R
Gan To Kagaku Ryoho; 2014 Jul; 41(7):811-6. PubMed ID: 25131865
[TBL] [Abstract][Full Text] [Related]
2. Phase-1 study of abiraterone acetate in chemotherapy-naïve Japanese patients with castration-resistant prostate cancer.
Matsubara N; Uemura H; Fukui I; Niwakawa M; Yamaguchi A; Iizuka K; Akaza H
Cancer Sci; 2014 Oct; 105(10):1313-20. PubMed ID: 25117615
[TBL] [Abstract][Full Text] [Related]
3. Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer.
Stein MN; Patel N; Bershadskiy A; Sokoloff A; Singer EA
Asian J Androl; 2014; 16(3):387-400. PubMed ID: 24759590
[TBL] [Abstract][Full Text] [Related]
4. Retreatment of men with metastatic castrate-resistant prostate cancer with abiraterone.
Leibowitz-Amit R; Alimohamed N; Vera-Badillo FE; Seah JA; Templeton AJ; Knox JJ; Tannock IF; Sridhar SS; Joshua AM
Prostate; 2014 Oct; 74(14):1462-4. PubMed ID: 25111736
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration-resistant prostate cancer after docetaxel-based chemotherapy.
Mulders PF; Molina A; Marberger M; Saad F; Higano CS; Chi KN; Li J; Kheoh T; Haqq CM; Fizazi K
Eur Urol; 2014 May; 65(5):875-83. PubMed ID: 24099659
[TBL] [Abstract][Full Text] [Related]
6. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature.
Sonpavde G; Attard G; Bellmunt J; Mason MD; Malavaud B; Tombal B; Sternberg CN
Eur Urol; 2011 Aug; 60(2):270-8. PubMed ID: 21550166
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone acetate: a guide to its use in metastatic castration-resistant prostate cancer.
Scott LJ; Yang LPH; Lyseng-Williamson KA
Drugs Aging; 2012 Mar; 29(3):243-248. PubMed ID: 22372727
[TBL] [Abstract][Full Text] [Related]
8. [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
Boissier E; Loriot Y; Vignot S; Massard C
Bull Cancer; 2014 Apr; 101(4):388-93. PubMed ID: 24793632
[TBL] [Abstract][Full Text] [Related]
9. [Mechanisms of resistance to CYP17A1 inhibitors in castrate resistant prostate cancer].
Ripert T; Crouzet S; Ploussard G; De La Taille A; Robert G
Prog Urol; 2013 Oct; 23 Suppl 1():S16-22. PubMed ID: 24314735
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate (Zytiga) for metastatic castration-resistant prostate cancer.
Med Lett Drugs Ther; 2011 Aug; 53(1370):63-4. PubMed ID: 21836546
[No Abstract] [Full Text] [Related]
11. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
Bedoya DJ; Mitsiades N
Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
[No Abstract] [Full Text] [Related]
12. Agents that target androgen synthesis in castration-resistant prostate cancer.
Ferraldeschi R; de Bono J
Cancer J; 2013; 19(1):34-42. PubMed ID: 23337755
[TBL] [Abstract][Full Text] [Related]
13. Response to subsequent docetaxel in a patient cohort with metastatic castration-resistant prostate cancer after abiraterone acetate treatment.
Aggarwal R; Harris A; Formaker C; Small EJ; Molina A; Griffin TW; Ryan CJ
Clin Genitourin Cancer; 2014 Oct; 12(5):e167-72. PubMed ID: 24787968
[TBL] [Abstract][Full Text] [Related]
14. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
15. Abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer: U.S. Food and Drug Administration drug approval summary.
Kluetz PG; Ning YM; Maher VE; Zhang L; Tang S; Ghosh D; Aziz R; Palmby T; Pfuma E; Zirkelbach JF; Mehrotra N; Tilley A; Sridhara R; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Dec; 19(24):6650-6. PubMed ID: 24150234
[TBL] [Abstract][Full Text] [Related]
16. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.
Logothetis CJ; Basch E; Molina A; Fizazi K; North SA; Chi KN; Jones RJ; Goodman OB; Mainwaring PN; Sternberg CN; Efstathiou E; Gagnon DD; Rothman M; Hao Y; Liu CS; Kheoh TS; Haqq CM; Scher HI; de Bono JS
Lancet Oncol; 2012 Dec; 13(12):1210-7. PubMed ID: 23142059
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
Salem M; Garcia JA
Curr Oncol Rep; 2011 Apr; 13(2):92-6. PubMed ID: 21243537
[TBL] [Abstract][Full Text] [Related]
18. Metabolic and prostate-specific antigen response after abiraterone acetate withdrawal: a new clinical scenario for castration-resistant prostate cancer?
Caffo O; Palermo A; Veccia A; Maines F; Chierichetti F; Galligioni E
Clin Genitourin Cancer; 2013 Dec; 11(4):e10-4. PubMed ID: 23810439
[No Abstract] [Full Text] [Related]
19. [Abiraterone acetate: a novel therapeutic option in hormone-refractory prostate cancer].
Turitto G; Di Bisceglie M; Moraca L; Sasso N; Sepede C; Suriano A; Romito S
Recenti Prog Med; 2012 Feb; 103(2):74-8. PubMed ID: 22430753
[TBL] [Abstract][Full Text] [Related]
20. How I do it: Prescribing abiraterone acetate for metastatic castration resistant prostate cancer.
Wang Y; Dason S; Shayegan B
Can J Urol; 2016 Aug; 23(4):8388-94. PubMed ID: 27544566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]